<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Toxoplasma pneumonia and other parasitic pulmonary infections in patients with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Toxoplasma pneumonia and other parasitic pulmonary infections in patients with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Toxoplasma pneumonia and other parasitic pulmonary infections in patients with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rajesh T Gandhi, MD, FIDSA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul E Sax, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Prior to the era of potent antiretroviral therapy, parasitic pulmonary infections were more commonly seen than they are today. However, the clinician still needs to be aware of presenting symptoms and signs of these uncommon infections, which may occur in the immunosuppressed patient with untreated or drug-resistant HIV infection. </p><p>This topic will address pulmonary infections related to <em>Toxoplasma gondii</em>, <em>Strongyloides stercoralis</em>, <em>Cryptosporidium</em>, and <em>Microsporidium </em>[<a href="#rid1">1</a>]. A more general overview of pulmonary disease in the patient with HIV is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3721.html" rel="external">"Evaluation of pulmonary symptoms in persons with HIV"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">TOXOPLASMOSIS</span><span class="headingEndMark"> — </span><em>T. gondii</em> is a ubiquitous intracellular protozoan. Although <em>T. gondii</em> can infect a wide range of vertebrates, feral and domestic cats are the definitive hosts. The organism undergoes its complete life cycle in the cat, resulting in the production of oocytes, which are passed with the feces into soil. Oocytes may remain infective for over one year. If ingested, <em>Toxoplasma</em> can invade tissue and reproduce. </p><p>The two routes of transmission to humans are:</p><p class="bulletIndent1"><span class="glyph">●</span>Ingestion of food or beverages contaminated with sporulated oocytes</p><p class="bulletIndent1"><span class="glyph">●</span>Transmission from mother to fetus.</p><p></p><p>There is no evidence of any other type of human-to-human transmission. Additional information on the transmission of toxoplasmosis is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Transmission'</a>.)</p><p class="headingAnchor" id="H3095112485"><span class="h2">Epidemiology</span><span class="headingEndMark"> — </span><em>T. gondii</em> is generally believed to cause subclinical infection in most immunocompetent hosts, but one review found that one-third of the reported cases of active pneumonia were in patients with no underlying immunosuppressive illness [<a href="#rid2">2</a>]. Of the remaining two-thirds, 61 percent had AIDS and 39 percent had other forms of immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients", section on 'Toxoplasmosis'</a>.)</p><p>Most active cases of <em>T. gondii</em> disease in people with AIDS are due to reactivation of latent infection. The age-adjusted <em>Toxoplasma</em> IgG seroprevalence in the United States is about 10 percent, with a higher prevalence in older people [<a href="#rid3">3</a>]. In people with HIV who are seropositive for <em>T. gondii</em>, it is estimated that approximately 30 percent will develop <em>Toxoplasma</em> encephalitis within two years of the initial diagnosis of AIDS without antiretroviral therapy (ART); another 1 percent who are seronegative will develop primary toxoplasmosis [<a href="#rid4">4,5</a>].</p><p>Although encephalitis is overwhelmingly the most common manifestation of <em>T. gondii</em> infection in patients with AIDS, pneumonitis has become its second most common presentation. The incidence of pneumonitis is unknown, but one report estimated the prevalence of <em>T. gondii</em> pneumonia in France to be 5 percent, based upon a prospective study of bronchoalveolar lavage (BAL) specimens in 169 patients with AIDS [<a href="#rid6">6</a>]. Rates in the United States seem to be much lower, which may be due to lower rates of latent infection. </p><p class="headingAnchor" id="H4"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>Active pulmonary toxoplasmosis does not usually occur in patients with HIV until the CD4 count falls below 100 cells/microL [<a href="#rid7">7</a>]. <em>Toxoplasma</em> pneumonitis typically presents with fever, nonproductive cough, and dyspnea. </p><p>The chest radiographs generally show diffuse bilateral interstitial and alveolar infiltrates. Other abnormalities include single or bilateral pulmonary nodules, cavitary infiltrates, lobar pneumonia, and pleural effusions. Reports of gallium scans in patients with <em>T. gondii</em> pneumonitis are rare, but diffuse intense uptake is reported. Serum lactate dehydrogenase (LDH) levels may be markedly elevated [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H5"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>Serologic tests for IgG, IgM, IgA, and IgE to <em>T. gondii</em> are available, but the results are usually not helpful in the profoundly immunosuppressed patient. However, the absence of IgG antibody to <em>T. gondii</em> does make the diagnosis much less likely, since most active disease is due to reactivation of latent infection.</p><p>If <em>Toxoplasma</em> pneumonitis is being considered, bronchoscopy with bronchoalveolar lavage (with or without transbronchial biopsy) is the preferred method of diagnosis, but its sensitivity and specificity are unknown [<a href="#rid9">9,10</a>]. The diagnosis is confirmed by observing the tachyzoite form of the organism in the BAL fluid or transbronchial biopsy. The most reliable methods of detection are Giemsa staining or eosin/<a class="drug drug_general" data-topicid="9636" href="/z/d/drug information/9636.html" rel="external">methylene blue</a> staining. The tachyzoite is 5 to 7 microns in length and is crescent-shaped. Polymerase chain reaction (PCR) testing has been used in patients with suspected pulmonary toxoplasmosis, but its performance characteristics are not known [<a href="#rid11">11,12</a>]. Immunofluorescence staining with a monoclonal antibody, or inoculation of mice followed by traditional culture may increase the yield of BAL, but these methods are not readily available [<a href="#rid13">13,14</a>].</p><p>If bronchoscopy is not diagnostic, then an open lung biopsy can be performed, either by video-assisted thoracoscopic surgery or traditional thoracotomy. Pathologically, a fibrinous exudate can be seen in the bronchi and alveoli, with an inflammatory cell interstitial infiltrate and areas of parenchymal necrosis. The organism may be seen within alveolar macrophages or freely floating within the alveoli. Unfortunately, the diagnosis of <em>Toxoplasma</em> pneumonitis is usually made by postmortem examination of the lungs, because it is often not considered premortem, and the special stains that are needed to make the diagnosis are not requested. </p><p class="headingAnchor" id="H1687013098"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Pulmonary toxoplasmosis may be clinically indistinguishable from other infections seen in patients with AIDS, such as <em>Pneumocystis jirovecii</em> (previously named <em>Pneumocystis carinii</em>) pneumonia, tuberculosis, cryptococcosis, or histoplasmosis. The differential diagnosis of pulmonary infiltrates in patients with AIDS is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3704.html" rel="external">"Epidemiology, clinical presentation, and diagnosis of Pneumocystis pulmonary infection in patients with HIV", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>The treatment of toxoplasmosis in patients with HIV includes antimicrobial therapy directed against <em>T. gondii</em>, as well as ART for immune recovery. (See <a class="local">'When to initiate antiretroviral therapy'</a> below.)</p><p>The combination of <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> and <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a> is the regimen of choice for treatment of toxoplasmosis. However, when access to pyrimethamine is limited, an alternative regimen (eg, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>) is required. The regimens used for pulmonary disease are the same as those used for <em>Toxoplasma</em> encephalitis since there are no controlled studies specifically designed for lung involvement. The preferred and alternative regimens are described in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Treatment'</a>.)</p><p>The exact duration of therapy for <em>Toxoplasma </em>pneumonitis is unknown. We generally administer three to six weeks of induction therapy, depending upon the severity of the disease and the response to treatment. Some studies suggest successful treatment outcomes in 50 to 77 percent of patients, although the number of cases of pulmonary toxoplasmosis is small [<a href="#rid2">2</a>].</p><p>Maintenance therapy (also called secondary prophylaxis) is prudent after initial treatment because relapses of toxoplasmosis may occur despite successful therapy [<a href="#rid15">15</a>]. The choice of regimen and the duration of maintenance therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Discontinuing maintenance therapy'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>For patients with HIV, the risk of developing toxoplasmosis can be reduced by avoiding exposure to the pathogen or by using prophylactic antibiotics to decrease the risk of reactivation. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV", section on 'Prevention'</a>.)</p><p class="headingAnchor" id="H2193258592"><span class="h1">OTHER PARASITIC PULMONARY INFECTIONS</span></p><p class="headingAnchor" id="H9"><span class="h2">Strongyloidiasis</span><span class="headingEndMark"> — </span><em>S. stercoralis</em> is an intestinal parasite that has a worldwide distribution but is predominantly found in tropical and subtropical areas, as well as the southeastern United States. The primary mode of transmission occurs when larvae from contaminated feces penetrate the skin, although infection can also occur via the fecal-oral route and from sexual transmission. </p><p>Most infected persons remain either asymptomatic or have low-grade abdominal symptoms. However, some patients, particularly those who are immunocompromised, can develop disseminated strongyloidiasis or the hyperinfection syndrome, both of which are considered "systemic strongyloidiasis" [<a href="#rid16">16,17</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>Disseminated strongyloidiasis occurs when the organism, in the larval form, is found outside the usual migration pattern.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperinfection is an augmentation of the life cycle, resulting in a heavy infestation of worms in the lungs.</p><p></p><p>There have only been scattered cases of systemic strongyloidiasis in patients with HIV [<a href="#rid16">16,18,19</a>]; indeed, HIV does not appear to be a risk factor for disseminated strongyloidiasis [<a href="#rid20">20</a>]. However, strongyloides should be considered in the differential diagnosis of patients with HIV and pulmonary disease if they have previously lived or currently reside in endemic areas. Other risk factors for developing hyperinfection secondary to strongyloidiasis include high-dose glucocorticoids, organ transplantation, and HTLV-1 infection. (See  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients", section on 'Strongyloides'</a>.)</p><p>The diagnosis and treatment of patients with HIV and pulmonary involvement due to strongyloides are the same as for other immunocompromised hosts. This is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5714.html" rel="external">"Strongyloidiasis", section on 'Severe disease'</a>.)</p><p class="headingAnchor" id="H15"><span class="h2">Cryptosporidium and microsporidium</span><span class="headingEndMark"> — </span><em>Cryptosporidium</em> and <em>Microsporidium</em> are causative agents of gastrointestinal disease in patients with HIV/AIDS. There are a few case reports of pulmonary disease due to these organisms in patients with AIDS before the introduction of effective antiretroviral therapy [<a href="#rid21">21-23</a>]. Fever and cough were the dominant symptoms. There are no specific treatment recommendations for pulmonary disease due to <em>Cryptosporidium </em>and<em> Microsporidium</em>; information about antiparasitic drugs that may be active against these organisms is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5731.html" rel="external">"Microsporidiosis", section on 'Patients with HIV'</a> and  <a class="medical medical_review" href="/z/d/html/16217.html" rel="external">"Cryptosporidiosis: Treatment and prevention", section on 'Patients with advanced HIV'</a>.)</p><p>Preventing exposure is the preferred method of prophylaxis, particularly in the patient with advanced immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/16217.html" rel="external">"Cryptosporidiosis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H1676837120"><span class="h1">WHEN TO INITIATE ANTIRETROVIRAL THERAPY</span><span class="headingEndMark"> — </span>All patients with HIV should receive antiretroviral therapy, regardless of the CD4 count and viral load. In treatment-naïve patients who present with one of the parasitic lung diseases described above, treatment should be initiated within two weeks of diagnosis. For those failing therapy, a new regimen should be constructed. Detailed discussions of how to select an antiretroviral regimen are presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a> and  <a class="medical medical_review" href="/z/d/html/13979.html" rel="external">"Selecting an antiretroviral regimen for treatment-experienced patients with HIV who are failing therapy"</a>.)</p><p class="headingAnchor" id="H3929594877"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H11946490"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Prior to the era of potent antiretroviral therapy (ART), parasitic pulmonary infections were more commonly seen than they are today. However, the clinician needs to be aware of the presenting symptoms and signs of these uncommon infections, which may still occur in the immunosuppressed patient with untreated or drug-resistant HIV infection. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Toxoplasma</em> pneumonitis generally presents with fever, nonproductive cough, and dyspnea. The chest radiographs generally show diffuse bilateral interstitial and alveolar infiltrates. Pulmonary toxoplasmosis does not usually occur in patients with HIV until the CD4 count falls below 100 cells/microL. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If <em>Toxoplasma </em>pneumonitis is being considered<em>, </em>bronchoscopy with bronchoalveolar lavage for examination of tachyzoites is the preferred method of diagnosis. If the diagnosis is confirmed, the treatment of choice is typically a regimen that contains <a class="drug drug_general" data-topicid="9841" href="/z/d/drug information/9841.html" rel="external">pyrimethamine</a> and <a class="drug drug_general" data-topicid="9960" href="/z/d/drug information/9960.html" rel="external">sulfadiazine</a>, which is generally administered for three to six weeks. After that, maintenance therapy should be administered until immune reconstitution is achieved with ART. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Treatment'</a> above and <a class="local">'When to initiate antiretroviral therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Strongyloides stercoralis</em> is an intestinal parasite that has a worldwide distribution. Disseminated strongyloidiasis can cause pulmonary infection in patients with HIV; however this is rare, since HIV does not appear to be a risk factor for disseminated infection. (See <a class="local">'Strongyloidiasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Cryptosporidium</em> and <em>Microsporidium</em> typically cause gastrointestinal disease in patients with HIV/AIDS. However, there are a few case reports of pulmonary disease due to these organisms in patients with AIDS. (See <a class="local">'Cryptosporidium and microsporidium'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients with HIV and <em>Toxoplasma</em> pneumonia or other parasitic pulmonary infections should receive ART, regardless of the CD4 count and viral load. In treatment-naïve patients, ART should be initiated within two weeks of diagnosis. (See <a class="local">'When to initiate antiretroviral therapy'</a> above.)</p><p></p><p class="headingAnchor" id="H2615549077"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Patricia A Tietjen, MD, who contributed to an earlier version of this topic review.</p><p>UpToDate also gratefully acknowledges John G Bartlett, MD (deceased), who contributed as Section Editor on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Skalski JH, Limper AH. Fungal, Viral, and Parasitic Pneumonias Associated with Human Immunodeficiency Virus. Semin Respir Crit Care Med 2016; 37:257.</a></li><li><a class="nounderline abstract_t">Pomeroy C, Filice GA. Pulmonary toxoplasmosis: a review. Clin Infect Dis 1992; 14:863.</a></li><li><a class="nounderline abstract_t">Jones JL, Kruszon-Moran D, Elder S, et al. Toxoplasma gondii Infection in the United States, 2011-2014. Am J Trop Med Hyg 2018; 98:551.</a></li><li><a class="nounderline abstract_t">Mariuz P, Bosler EM, Luft BJ. Toxoplasmosis in individuals with AIDS. Infect Dis Clin North Am 1994; 8:365.</a></li><li><a class="nounderline abstract_t">Holliman RE. Serological study of the prevalence of toxoplasmosis in asymptomatic patients infected with human immunodeficiency virus. Epidemiol Infect 1990; 105:415.</a></li><li><a class="nounderline abstract_t">Derouin F, Sarfati C, Beauvais B, et al. Prevalence of pulmonary toxoplasmosis in HIV-infected patients. AIDS 1990; 4:1036.</a></li><li><a class="nounderline abstract_t">Bonilla CA, Rosa UW. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome: diagnosis by bronchoalveolar lavage. South Med J 1994; 87:659.</a></li><li><a class="nounderline abstract_t">Pugin J, Vanhems P, Hirschel B, et al. Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia. N Engl J Med 1992; 326:1226.</a></li><li><a class="nounderline abstract_t">Oksenhendler E, Cadranel J, Sarfati C, et al. Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome. Am J Med 1990; 88:18N.</a></li><li><a class="nounderline abstract_t">Maguire GP, Tatz J, Giosa R, Ahmed T. Diagnosis of pulmonary toxoplasmosis by bronchoalveolar lavage. N Y State J Med 1986; 86:204.</a></li><li><a class="nounderline abstract_t">Desoubeaux G, Cabanne É, Franck-Martel C, et al. Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosis. J Clin Pathol 2016; 69:726.</a></li><li><a class="nounderline abstract_t">Wu Y, Wang F, Wang C, et al. Detection of Pneumocystis jirovecii and Toxoplasma gondii in patients with lung infections by a duplex qPCR assay. PLoS Negl Trop Dis 2021; 15:e0010025.</a></li><li><a class="nounderline abstract_t">Derouin F, Sarfati C, Beauvais B, et al. Laboratory diagnosis of pulmonary toxoplasmosis in patients with acquired immunodeficiency syndrome. J Clin Microbiol 1989; 27:1661.</a></li><li><a class="nounderline abstract_t">Burg JL, Grover CM, Pouletty P, Boothroyd JC. Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction. J Clin Microbiol 1989; 27:1787.</a></li><li><a class="nounderline abstract_t">Lane HC, Laughon BE, Falloon J, et al. NIH conference. Recent advances in the management of AIDS-related opportunistic infections. Ann Intern Med 1994; 120:945.</a></li><li><a class="nounderline abstract_t">Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.</a></li><li><a class="nounderline abstract_t">Satoh M, Kiyuna S, Shiroma Y, et al. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol 2003; 133:391.</a></li><li><a class="nounderline abstract_t">Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.</a></li><li><a class="nounderline abstract_t">Maayan S, Wormser GP, Widerhorn J, et al. Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome. Am J Med 1987; 83:945.</a></li><li><a class="nounderline abstract_t">Siegel MO, Simon GL. Is human immunodeficiency virus infection a risk factor for Strongyloides stercoralis hyperinfection and dissemination. PLoS Negl Trop Dis 2012; 6:e1581.</a></li><li><a class="nounderline abstract_t">Mannheimer SB, Soave R. Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis. Infect Dis Clin North Am 1994; 8:483.</a></li><li><a class="nounderline abstract_t">Forgacs P, Tarshis A, Ma P, et al. Intestinal and bronchial cryptosporidiosis in an immunodeficient homosexual man. Ann Intern Med 1983; 99:793.</a></li><li><a class="nounderline abstract_t">Weber R, Kuster H, Visvesvara GS, et al. Disseminated microsporidiosis due to Encephalitozoon hellem: pulmonary colonization, microhematuria, and mild conjunctivitis in a patient with AIDS. Clin Infect Dis 1993; 17:415.</a></li></ol></div><div id="topicVersionRevision">Topic 3714 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26974302" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fungal, Viral, and Parasitic Pneumonias Associated with Human Immunodeficiency Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1576281" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pulmonary toxoplasmosis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29260660" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Toxoplasma gondii Infection in the United States, 2011-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089465" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Toxoplasmosis in individuals with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2209744" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Serological study of the prevalence of toxoplasmosis in asymptomatic patients infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2261121" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Prevalence of pulmonary toxoplasmosis in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8202779" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome: diagnosis by bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1557107" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Extreme elevations of serum lactic dehydrogenase differentiating pulmonary toxoplasmosis from Pneumocystis pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2368769" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Toxoplasma gondii pneumonia in patients with the acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3459072" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnosis of pulmonary toxoplasmosis by bronchoalveolar lavage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26729012" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Pulmonary toxoplasmosis in immunocompromised patients with interstitial pneumonia: a single-centre prospective study assessing PCR-based diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34919557" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Detection of Pneumocystis jirovecii and Toxoplasma gondii in patients with lung infections by a duplex qPCR assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2671023" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Laboratory diagnosis of pulmonary toxoplasmosis in patients with acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2768467" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Direct and sensitive detection of a pathogenic protozoan, Toxoplasma gondii, by polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909657" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : NIH conference. Recent advances in the management of AIDS-related opportunistic infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7934810" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930366" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8325052" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3674100" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Strongyloides stercoralis hyperinfection in a patient with the acquired immune deficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22860137" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is human immunodeficiency virus infection a risk factor for Strongyloides stercoralis hyperinfection and dissemination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8089473" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Protozoal infections in patients with AIDS. Cryptosporidiosis, isosporiasis, cyclosporiasis, and microsporidiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6651023" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intestinal and bronchial cryptosporidiosis in an immunodeficient homosexual man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8218683" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Disseminated microsporidiosis due to Encephalitozoon hellem: pulmonary colonization, microhematuria, and mild conjunctivitis in a patient with AIDS.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
